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Abstract
The occurrence of large publically available repositories of human breast tumor gene expression profiles provides an
important resource to discover new breast cancer biomarkers and therapeutic targets. For example, knowledge of the
expression of the estrogen and progesterone hormone receptors (ER and PR), and that of the ERBB2 in breast tumor
samples enables choice of therapies for the breast cancer patients that express these proteins. Identifying new biomarkers
and therapeutic agents affecting the activity of signaling pathways regulated by the hormone receptors or ERBB2 might be
accelerated by knowledge of their expression levels in large gene expression profiling data sets. Unfortunately, the status of
these receptors is not invariably reported in public databases of breast tumor gene expression profiles. Attempts have been
made to employ a single probe set to identify ER, PR and ERBB2 status, but the specificity or sensitivity of their prediction is
low. We enquired whether estimation of ER, PR and ERBB2 status of profiled tumor samples could be improved by using
multiple probe sets representing these three genes and others with related expression. We used 8 independent datasets of
human breast tumor samples to define gene expression signatures comprising 24, 51 and 14 genes predictive of ER, PR and
ERBB2 status respectively. These signatures, as demonstrated by sensitivity and specificity measures, reliably identified
hormone receptor and ERBB2 expression in breast tumors that had been previously determined using protein and DNA
based assays. Our findings demonstrate that gene signatures can be identified which reliably predict the expression status
of the estrogen and progesterone hormone receptors and that of ERBB2 in publically available gene expression profiles of
breast tumor samples. Using these signatures to query transcript profiles of breast tumor specimens may enable discovery
of new biomarkers and therapeutic targets for particular subtypes of breast cancer.
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Introduction
The accurate assessment of the expression of the estrogen and
progesterone hormone receptors (ER and PR) and that of ERBB2
is essential to select the appropriate therapy for breast cancer
patients [1,2,3,4,5]. Knowledge of the expression of the latter
biomarkers is also advantageous to develop new therapies that
may target specific subtypes of breast cancer [6,7]. ER and PR
status is routinely defined by immunohistochemistry (IHC),
whereas that of ERBB2 is determined by either IHC or by
fluorescence in-situ hybridization (FISH) [8,9]. However, despite
standardization of the methods used to define the status of the
hormone receptors and ERBB2 in clinical laboratories, there is a
level of subjectivity in these measurements, leading to variability
among results obtained by different pathologists and laboratories
[10,11,12,13]. It has been suggested that more accurate and less
subjective methods would improve the classification of human
breast tumors [14].
Global gene expression profiling is widely used to examine the
expression of thousands of genes in biological samples [15].
Indeed, this technology has been used extensively in numerous
breast cancer studies to: examine the effects of various therapies on
gene transcripts [16,17]; identify differences in gene expression
among different tumor tissues [18,19,20,21]; molecularly classify
tumors [22,23,24]; and to predict prognosis [25,26,27] and
treatment outcomes [28,29,30]. Attempts to use gene expression
profiles to identify the ER, PR and ERBB2 status of human breast
tumors have also been reported [14,31,32]. A single probe set
representative of each gene was informative to establish ER, PR
and ERBB2 expression in breast tumor samples. However, we
wondered whether the specificity and/or sensitivity of this method
could be improved by using probe sets representative of multiple
genes (gene signatures) whose expression correlated with that of
the hormone receptors and ERBB2.
Many peer-reviewed journals require authors to deposit
microarray data in public depositories, such as the Gene
Expression Omnibus [33] or ArrayExpress [34], thereby
making them publicly available for various applications [35].
However, clinical information such as hormone receptor or
ERBB2 status of breast tumor samples is not invariably
provided with their global gene expression profiles. Knowledge
of hormone receptor and ERBB2 status as well as the global
gene expression profiles of breast tumor samples may permit
more accurate prognostic tests to be developed and would
strengthen the value of the many breast tumor gene expression
profiles in public depositories.
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26023Here we used 8 independent datasets containing human breast
tumor samples profiled on Affymetrix GeneChips to define gene
expression signatures predictive of their ER and PR status as well
as that of ERBB2. These gene signatures reliably predicted the
status of the hormone receptors and that of ERBB2 as assessed by
protein (IHC) or DNA (FISH) based tests. Because the largest
predictive signature defined in our study comprises only 51 genes,
a qRT-PCR based format may be developed that could provide an
objective and relatively high-throughput alternative for the IHC-
based definitions of hormone receptor and ERBB2 status in
patient samples.
Results
ER status
Figure 1 shows the specificity and sensitivity values for sets of
genes predictive of ER status selected by using Spearman rank
correlation cutoffs between 0.42 and 0.48. To find the most
predictive set of genes, we selected those that yielded the highest
combination (here the sum) of specificity and sensitivity values.
The identified gene signature consisted of 35 probe sets,
representing 24 annotated genes (Table 1). Of these 24 genes,
one is the ESR1 itself, whereas 11 are related to the expression of
the ER: the latter include genes (GATA3, GFRA1, IL6ST, and
STC2) whose expression correlates positively with that of the ER
[36,37,38]; genes (CA12, CYP2B6, GREB1, LIV1, TFF1, and
KDM4B) whose expression is positively regulated by the ER
[37,39,40,41,42,43]; and a gene located in close proximity to
ESR1 (C6orf97) [44], and whose expression is therefore positively
correlated with that of the ER. Importantly, several of these genes
are represented by multiple probe sets indicating that they robustly
detect their cognate transcripts in breast tumor RNA samples
(Table 1). Twelve remaining genes (ADCY9, ANXA9, AMFR,
CELSR1, CYP2B7P1, FAM176B, GAMT, KCNK15, SCCPDH,
SCUBE2, SSH3, and TBC1D9) have not been previously associated
with ER status. Interestingly, SCUBE2 is reported to positively
correlate with PR status [45]. Because our ER signature comprises
24 genes and one probe set for an unknown gene, we refer to the
signature as the ‘‘24-gene ER signature’’. The 24-gene ER
signature separated ER-positive tumors from ER-negative tumors
with an accuracy of 88.66%, sensitivity of 91.18%, specificity of
88.26%, PPV (Positive Predictive Value) of 98.43% and NPV
(Negative Predictive Value) of 55.36% in the 247 training samples
(Table 2; p,2.2?10
216, Fisher’s exact test). To determine whether
the predictive performance of a single probe set is sufficient to
determine ER status of a sample we used ‘‘205225_at’’, the probe
set with the highest Spearman rank correlation in the 24-gene ER
signature (Spearman rank correlation is 0.50; see Table S1), which
we termed ‘‘best probe set’’ for the ER predictive signature. It is of
interest, that the ‘‘best probe set’’ was the same probe set
conventionally used to determine ER status (205225_at; see Table
S1). The prediction accuracy of the ‘‘best probe set’’ was 89.07%,
sensitivity 89.67%, specificity 85.29%, PPV 97.45% and NPV
56.86% (Table 2; p,2.2?10
216, Fisher’s exact test). Both the
sensitivity and specificity of prediction by using the ‘‘best probe
set’’ were lower than were the sensitivity and the specificity of the
prediction using the 24-gene ER signature, indicating that the
predictive performance of the single ‘‘best probe set’’ is not as high
as the performance of our signature.
We subsequently tested the predictive performance of the 24-
gene signature in 5 independent validation datasets (Table 2).
The first validation set (GSE2034) comprised 286 samples; the
Figure 1. Selecting gene signature predictive of ER status based on sensitivity and specificity. The cutoff is based on Spearman rank
correlation coefficients. The number of probe sets in each signature is marked by the number under the lowest curve. Black filled circles – specificity;
gray circles – sensitivity; black line – sum of specificity and sensitivity. The optimal number of probe sets was 35, with Spearman rank correlation
coefficient cutoff set at 0.43. Gray line and ‘‘*’’ indicate the sum of specificity and sensitivity of the prediction obtained by using a single ‘‘best probe
set’’ (‘‘205225_at’’).
doi:10.1371/journal.pone.0026023.g001
ER, PR and ERBB2 Status in Breast Tumor Profiles
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26023prediction accuracy was 87.76%, sensitivity 87.56%, specificity
88.31%, PPV 95.31% and NPV 72.34% (Table 2; p,2.2?10
216,
Fisher’s exact test). The second validation set (GSE7390)
comprised 198 samples; the prediction accuracy was 88.89%,
sensitivity 92.54%, specificity 81.25%, PPV 91.18% and NPV
83.87% (Table 2; p,2.2?10
216, Fisher’s exact test). The third
validation set (GSE2603) is composed of 97 samples; the
prediction accuracy was 97.94%, sensitivity 96.43%, specificity
100%, PPV 100% and NPV 95.35% (Table 2; p,2.2?10
216,
Fisher’s exact test). The fourth validation set (GSE20271)
contained 144 samples; the prediction accuracy was 79.86%,
sensitivity 79.22%, specificity 80.60%, PPV 82.43% and NPV
77.14% (Table 2; p=4.227?10
213, Fisher’s exact test). The final
validation dataset (GSE20194) comprised 278 samples; the
prediction accuracy was 89.93%, sensitivity 89.63%, specificity
90.35%, PPV 93.04% and NPV 85.83% (Table 2; p,2.2?10
216,
Fisher’s exact test).
Figure 2 and Table S4 depict the sensitivity and specificity levels
obtained for the training and the validation sets using the 24-gene
ER signature, compared to those derived by using the conven-
tional method of employing a single probe set (205225_at). The
sensitivity levels obtained by using a single probe set were relatively
Table 1. Gene signature predictive of ER status.
Gene Symbol Correlation Coefficient Gene Title
ADCY9 0.44 adenylatecyclase 9
AMFR 0.44 autocrine motility factor receptor
ANXA9 0.43 annexin A9
0.45
C6orf97 0.45 chromosome 6 open reading frame 97
CA12 0.48 carbonic anhydrase XII
0.48
0.47
0.47
0.47
CELSR1 0.43 cadherin, EGF LAG seven-pass G-type receptor 1
(flamingo homolog, Drosophila)
CYP2B6 /// 0.45 cytochrome P450, family 2, subfamily B, polypeptides 6, 7
CYP2B7P1
ESR1 0.50 estrogen receptor 1
FAM176B 0.46 family with sequence similarity 176, member B
0.43
GAMT 0.45 guanidinoacetate N-methyltransferase
GATA3 0.45 GATA binding protein 3
0.48
0.47
GFRA1 0.45 GDNF family receptor alpha 1
GREB1 0.46 growth regulation by estrogen in breast cancer 1
IL6ST 0.44 interleukin 6 signal transducer (gp130, oncostatin M receptor)
0.44
KCNK15 0.44 potassium channel, subfamily K, member 15
KDM4B 0.45 lysine (K)-specific demethylase 4B
0.46
0.43
SCCPDH 0.43 saccharopine dehydrogenase (putative)
SCUBE2 0.46 signal peptide, CUB domain, EGF-like 2
LIV1 (SLC39A6) 0.46 solute carrier family 39 (zinc transporter), member 6
SSH3 0.44 slingshot homolog 3 (Drosophila)
STC2 0.44 stanniocalcin 2
TBC1D9 0.43 TBC1 domain family, member 9 (with GRAM domain)
TFF1 0.44 trefoil factor 1
Unknown 0.45 Not annotated
Each row in the coefficient column represents a probe set. Genes, whose levels of expression were previously reported to correlate with ER status are marked in bold.
The rows were sorted alphabetically according to the Gene Symbol. For detailed information on the probe sets see Table S1.
doi:10.1371/journal.pone.0026023.t001
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(GSE2603); however, the specificity levels were significantly lower
than these obtained using the 24-gene ER signature, ranging
between 68.29% (GSE2603) and 85.96% (GSE20194; p,0.05,
t-test). Hence the 24-gene ER signature significantly improved the
specificity levels of ER status prediction (p,0.05, t-test) to range
between 80.6% and 100% without adversely affecting sensitivity
levels.
ERBB2 status
Figure 3 shows the specificity and sensitivity values for gene sets
predictive of ERBB2 status selected by using Spearman rank
correlation cutoffs between 0.34 and 0.39. For the first training set
(GSE2603; Figure 3, left panel), the sum of specificity and sensitivity
was constant for the examined range of Spearman rank correlation
cutoffs. Therefore, we used an additional set of samples for
training (GSE20271; Figure 3, right panel), which led to the highest
combination of specificity and sensitivity values at a cutoff of 0.35,
yielding a gene signature consisting of 14 annotated genes
(represented by 18 probe sets) and 1 probe set representing an
unknown sequence ( Table 3). The ERBB2 gene and 5 other genes
(CRK7, GRB7, PERLD1, PPARBP, and STARD3) are part of the
17q12-q21 amplicon and are reported to be co-amplified with the
ERBB2 locus [46]. Several of these genes are represented by a
number of probe sets indicating that they readily detect their
cognate transcripts in breast tumor RNA samples (Table 3). The
remaining 8 genes comprising the candidate ERBB2 gene
signature have not previously been reported to correlate with
ERBB2 expression. Because our signature comprises 14 genes and
one probe set representing an unannotated gene we henceforth
Table 2. Correlation of microarray–based expression profiling data with routinely established ER status.
Total
ER status defined
by predictor Clinical ER status
Negative Positive p-value*
Training GSE3494 247 Negative 31 25 ,2.2?10–16
Positive 3 188
GSE3494** 247 Negative 29 22 ,2.2?10–16
Positive 5 191
Validation GSE2034 286 Negative 68 26 ,2.2?10–16
Positive 9 183
GSE7390 198 Negative 52 10 ,2.2?10–16
Positive 12 124
GSE2603 97 Negative 41 2 ,2.2?10–16
Positive 0 54
GSE20271 144 Negative 54 16 4.227?10–13
Positive 13 61
GSE20194 278 Negative 103 17 ,2.2?10–16
Positive 11 147
*Fisher’s exact test.
**The analysis was performed by using the ‘‘best probe set’’ (‘‘205225_at’’). The rest of analyses were performed by using the 24-gene ER signature.
doi:10.1371/journal.pone.0026023.t002
Figure 2. ER status determination: sensitivity (‘+’) and specificity (‘-’) obtained with two different microarray-based methods. The
improved feature is highlighted by gray background. * Training set.
doi:10.1371/journal.pone.0026023.g002
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The 14-gene ERBB2 signature separated ERBB2-positive tumors
from ERBB2-negative tumors with an accuracy of 93.18%,
sensitivity of 77.78%, specificity of 94.94%, PPV of 63.64% and
NPV of 97.40% in the 88 training samples of the first training
set (GSE2603; Table 4; p=1.712?10
26, Fisher’s exact test).
The second training set (GSE20271) comprised 144 breast
tumor profiles: the prediction accuracy was 88.89%, sensitivity
59.09%, specificity 94.26%, PPV 65.0%% and NPV 92.74%
(Table 4; p =2.287?10
28, Fisher’s exact test). To determine
whether the predictive performance of a single probe set is sufficient
to determine ERBB2 status, we used the ‘‘203497_at’’, the probeset
with the highest Spearman rank correlation in the 14-gene ERBB2
signature (Spearman rank correlation is 0.45; see Table S2), which
we termed the ‘‘best probe set’’ for the ERBB2 predictive signature.
For the first training set (GSE2603) the predictive accuracy of the
‘‘best probe set’’ was 96.59%, sensitivity 87.5%, specificity 97.5%,
PPV 77.78% and NPV 98.73% (Table 4; p,4.4?10
28 , Fisher’s
exact test). For the second training set (GSE20271) the predictive
accuracy of the ‘‘best probe set’’ was 86.11%, sensitivity 40.91%,
specificity 94.26%, PPV 56.25% and NPV 89.84% (Table 4;
p,5.2?10
25, Fisher’s exact test). Although predictions by using
‘‘best probe set’’ in both training sets provided similar results, the
sensitivity of prediction by using the ‘‘best probe set’’ in the second
training set (GSE20271) was very low, reaching 40.91%. Therefore,
we suggest that the predictive performance of the 14-gene ERBB2
signature is better than that of the single ‘‘best probe set’’.
We tested the predictive performance of the 14-gene signature
in 2 validation sets (Table 4). The first validation set (GSE20194) is
composed of 278 breast tumor profiles; the prediction accuracy
was 94.60%, sensitivity 76.27%, specificity 99.54%, PPV 97.83%
and NPV 93.97% (Table 4; p,2.2?10
216, Fisher’s exact test). For
the second validation set (GSE16446; 93 breast tumor profiles), the
prediction accuracy was 93.55%, sensitivity 83.07%, specificity
98.39%, PPV 96.30% and NPV 92.42% (Table 4; p,2.2?10
216,
Fisher’s exact test). Importantly, the second validation set was
obtained from transcript profiles performed on a different type of
GeneChip – HG-U133 Plus 2.0. We performed this last validation
on data collected from HG-U133 Plus 2.0 GeneChips to
determine whether the candidate 14-gene ERBB2 signature was
capable of separating ERBB2-positive tumors from their ERBB2-
negative counterparts independent of the nature of the Affymetrix
arrays to which the transcripts were hybridized.
Figure 4 and Table S4 depict sensitivity and specificity levels
obtained for the training and the validation sets using the 14-gene
ERBB2 signature or using the method employing a single probe
set (216836_s_at). The specificity levels obtained by using one
probe set were relatively high, ranging between 94.94%
(GSE2603) and 99.54% (GSE20194); however, the sensitivity
levels were significantly lower, ranging between 54.55%
(GSE20271) and 77.78% (GSE2603). Whereas the specificity
levels were approximately within the same range using the 14-
gene ERBB2 signature, the sensitivity levels changed to range
between 59.09% (GSE20271) and 77.78% (GSE2603). Impor-
Figure 3. Selecting set of genes predictive of ERBB2 status based on sensitivity and specificity. Cutoff is based on Spearman rank
correlation coefficients. The number of probe sets in each signature is marked by the number under the lowest curve. Black filled circles – specificity;
gray circles – sensitivity; black line – sum of specificity and sensitivity. The optimal number of probe sets was 19, with Spearman correlation
coefficient cutoff set at 0.35. Gray line and ‘‘*’’ indicate the sum of specificity and sensitivity of the prediction obtained by using a single ‘‘best probe
set’’ (‘‘203497_at’’).
doi:10.1371/journal.pone.0026023.g003
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with HG-133 Plus 2 array (GSE16446) lie within the 95%
confidence interval for both sensitivity (CI95%: 45.26–96.84) and
specificity (CI95%: 89.11 – 103.4) obtained for HG-U133A
arrays, for which our 14-gene ERBB2 signature was originally
developed.
Table 4. Correlation of microarray–based expression profiling data with routinely established ERBB2 status.
Total
ERBB2 status defined
by predictor Clinical ERBB2 status
Negative Positive p-value*
Training GSE2603 88 Negative 75 2 1.712?10
26
Positive 4 7
GSE2603** 88 Negative 78 1 ,4.4?10
28
Positive 2 7
GSE20271 144 Negative 115 9 2.287?10
28
Positive 7 13
GSE20271** 144 Negative 115 13 ,5.2?10
25
Positive 7 9
Validation GSE20194 278 Negative 218 14 ,2.2?10
216
Positive 1 45
GSE16446 93 Negative 61 5 ,2.2?10
216
Positive 1 26
*Fisher’s exact test.
**The analysis was performed by using the ‘‘best probe set’’ (‘‘203497_at’’). The rest of analyses were performed by using the 14-gene ERBB2 signature.
doi:10.1371/journal.pone.0026023.t004
Table 3. Gene signature predictive of ERBB2 status.
Gene Symbol Correlation Coefficient Gene description
Positive Spearman correlation
CRK7 (CDK12) 0.38 cyclin-dependent kinase 12
ERBB2 0.42 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2,
neuro/glioblastoma derived oncogene homolog (avian)
0.39
F2RL1 0.35 coagulation factor II (thrombin) receptor-like 1
GRB7 0.43 growth factor receptor-bound protein 7
IDI1 0.37 isopentenyl-diphosphate delta isomerase 1
ITGB6 0.36 integrin, beta 6
0.35
PERLD1 0.37 post-GPI attachment to proteins 3
0.38
PPARBP 0.45 mediator complex subunit 1
0.39
SEC63 0.37 SEC63 homolog (S. cerevisiae)
STARD3 0.37 StAR-related lipid transfer (START) domain containing 3
TRIM26 0.36 tripartite motif-containing 26
Negative Spearman correlation
DIRAS2 -0.36 DIRAS family, GTP-binding RAS-like 2
DUSP24 -0.36 serine/threonine/tyrosine interacting-like 1
UBTF -0.36 upstream binding transcription factor, RNA polymerase I
Unknown -0.37 Not annotated
Each row in the correlation coefficient column represents a probe set. Genes, within the borders of the ERBB2 amplicon are marked in bold. The list of genes is divided
into genes with positive and negative (-) correlation coefficients. For detailed information on the probe sets see Table S2.
doi:10.1371/journal.pone.0026023.t003
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Figure 5 shows specificity and sensitivity values for genes
predictive of PR status selected by using Spearman rank
correlation cutoffs between 0.35 and 0.42. The highest combina-
tion of specificity and sensitivity values was with a cutoff of 0.38,
yielding a gene signature comprising 51 annotated genes
(represented by 61 probe sets; Table 5). The PR gene, PGR, and
3 other genes (GATA3, STC2 and GLI3) [47,48,49] are increased in
their expression, whereas the expression of 6 genes (AURKA,
BUB1, CDC20, MKI67, HJURP, and CENPA) [50,51,52,53,54] is
Figure 4. ERBB2 status determination: sensitivity (‘+’) and specificity (‘-’) obtained with two different microarray-based methods.
The improved feature is highlighted by gray background. Datasets GSE2603, GSE20271 and GSE20194 were profiled on HG-U133A GeneChips;
GSE16446 was profiled on HG-U133 Plus 2.0 GeneChips. * Training set.
doi:10.1371/journal.pone.0026023.g004
Figure 5. Selecting set of genes predictive of PR status based on sensitivity and specificity. The cutoff is based on Spearman rank
correlation coefficients. The number of probe sets in each signature is marked by the number under the lowest curve. Black filled circles – specificity;
gray circles – sensitivity; black line – sum of specificity and sensitivity. The optimal number of probe sets is 61, with Spearman correlation coefficient
cutoff set at 0.38. Gray line and ‘‘*’’ indicate the sum of specificity and sensitivity of the prediction obtained by using a single ‘‘best probe set’’
(‘‘219197_s_at’’).
doi:10.1371/journal.pone.0026023.g005
ER, PR and ERBB2 Status in Breast Tumor Profiles
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26023Table 5. Gene signature predictive of PR status.
Gene Symbol Correlation Coefficient Gene Title
Positive Spearman correlation
BBS1 0.40 Bardet-Biedl syndrome 1
0.40
BCAM 0.40 basal cell adhesion molecule (Lutheran blood group)
CA12* 0.39 carbonic anhydrase XII
0.40
CASC1 0.39 cancer susceptibility candidate 1
FAM176B 0.41 family with sequence similarity 176, member B
0.44
GAMT 0.40 guanidinoacetate N-methyltransferase
GATA3* 0.39 GATA binding protein 3
0.41
GFRA1* 0.39 GDNF family receptor alpha 1
GLI3 0.39 GLI family zinc finger 3
HPN 0.39 hepsin
IL6ST* 0.40 interleukin 6 signal transducer (gp130, oncostatin M receptor)
0.41
KDM4B* 0.41 lysine (K)-specific demethylase 4B
0.42
LAMB2 0.40 laminin, beta 2 (laminin S)
LRRC17 0.39 leucine rich repeat containing 17
LZTFL1 0.39 leucine zipper transcription factor-like 1
MAGED2 0.39 melanoma antigen family D, 2
MAPT 0.39 microtubule-associated protein tau
0.40
PDE4A 0.38 phosphodiesterase 4A, cAMP-specific (phosphodiesterase E2 dunce homolog, Drosophila)
PGR 0.41 progesterone receptor
SCUBE2 0.44 signal peptide, CUB domain, EGF-like 2
LIV1 (SLC39A6)* 0.38 solute carrier family 39 (zinc transporter), member 6
STARD13 0.39 StAR-related lipid transfer (START) domain containing 13
STC2* 0.38 stanniocalcin 2
WDR19 0.40 WD repeat domain 19
Unknown 0.40 Not annotated
Negative Spearman correlation
AURKA 20.40 aurora kinase A
20.38
BUB1 20.41 budding uninhibited by benzimidazoles 1 homolog (yeast)
C16orf61 20.38 chromosome 16 open reading frame 61
CCNA2 20.40 cyclin A2
CDC20 20.40 cell division cycle 20 homolog (S. cerevisiae)
CDCA8 20.39 cell division cycle associated 8
CENPA 20.38 centromere protein A
CENPN 20.38 centromere protein N
CEP55 20.39 centrosomal protein 55 kDa
DBF4 20.44 DBF4 homolog (S. cerevisiae)
DDX39 20.39 DEAD (Asp-Glu-Ala-Asp) box polypeptide 39
DLGAP5 20.39 discs, large (Drosophila) homolog-associated protein 5
GATAD2A 20.41 GATA zinc finger domain containing 2A
GTSE1 20.38 G-2 and S-phase expressed 1
HJURP 20.39 Holliday junction recognition protein
ER, PR and ERBB2 Status in Breast Tumor Profiles
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26023decreased in PR-positive breast tumors. GATA3 is expressed in
normal mammary epithelial luminal progenitor cells and in the
luminal A molecular subtype (ER and/or PR positive tumors) of
human breast tumors [24,55]. Interestingly 11 of the genes
comprising the candidate PR gene signature also appeared in the
list of genes predictive of ER status (Tables 1 and 5): these genes
include CA12, FAM176B, GAMT, GATA3, GFRA1, IL6ST,
KDM4B, SCUBE2, LIV1, STC2 and an un-annotated probe set.
The expression levels of CA12, LIV1, KDM4B, STC2, GFRA1,
ILST6, and GATA3 are reported to positively correlate with that of
ER [36,37,38,39,41,42]. Our results show that all of these 11
genes appear to be up-regulated in both ER-positive and PR-
positive samples (see correlation coefficients in Tables 1 and 5).
Because our signature comprised 51 genes and one probe set for
an unannotated gene we refer to this signature as a ‘‘51-gene PR
signature’’. The candidate 51-gene PR signature contained 2
genes (HPN and MAPT) whose expression was reported to
correlate positively with ER expression [37,56]; however, these
genes did not appear in the ER-predictive signature. The
expression of 41 genes out of the 51 annotated genes constituting
the PR-predictive signature has not been previously associated
with PR status.
The candidate 51-gene PR signature separated PR-positive
tumors from PR-negative tumors with an accuracy of 81.27%,
sensitivity of 83.68%, specificity of 73.77%, PPV of 90.86% and
NPV of 59.21% in the 251 training samples (Table 6;
p=2.3?10
216, Fisher’s exact test). To determine whether the
predictive performance of a single probe set is sufficient to
determine PR status we used ‘‘219197_s_at’’, the probe set with
the highest Spearman rank correlation in the 51-gene PR
signature (Spearman rank correlation is 0.44; see Table S3),
which we termed ‘‘best probe set’’ for PR predictive signature.
The prediction accuracy of the ‘‘best probe set’’ was 80.48%,
sensitivity 91.05%, specificity 47.54%, PPV 84.39% and NPV
63.04% (Table 6; p,3.3?10
210, Fisher’s exact test). Although the
sensitivity of the prediction by using the ‘‘best probe set’’ was
higher than the sensitivity of the prediction by using the 51-gene
PR signature, the specificity was very low, reaching only 47.54%.
Also the prediction accuracy and PPV were lower when using only
the ‘‘best probe set’’. These findings indicated that the predictive
performance of the single ‘‘best probe set’’ is not as high as the
performance of the signature.
We tested the predictive performance of the 51-gene PR
signature in 3 validation datasets (Table 6). The prediction
accuracy was 78.47%, sensitivity 76.92%, specificity 79.75%, PPV
75.76% and NPV 80.77% in 144 samples of the first validation set
(GSE20271; Table 6; p=6.1?10
212, Fisher’s exact test). The
prediction accuracy was 74.1%, sensitivity 81.82%, specificity
68.15%, PPV 66.44% and NPV 82.94% in 278 profiles of the
second validation set (GSE20194; Table 6; p,2.2?10
216, Fisher’s
exact test); however, in the third validation set (HG-U133 Plus 2.0
GeneChip array) the prediction accuracy was 62.03%, sensitivity
62.5%, specificity 60.0%, PPV 86.96%, and NPV 27.27% in 79
samples (GSE9195; Table 6; p=0.1484, Fisher’s exact test).
Figure 6 and Table S4 depict sensitivity and specificity levels
obtained for the training and the validation sets by using the
candidate 51-gene PR gene signature or by using a single probe set
(208305_at) to assess PR status in breast tumor specimens. The
estimation was performed in the same way as was reported
previously to establish PR status based on gene expression profiles.
The specificity levels obtained by using a single probe set were
relatively high, ranging between 77.05% (GSE3494) and 98.73%
(GSE20271); however, the sensitivity levels were lower, ranging
between 32.31% (GSE20271) and 65.79% (GSE3494). Whereas
using the 51-gene PR signature the specificity levels did not change
significantly (p=0.134, t-test) compared to those using the single
probe set, the sensitivity levels were significantly improved
(p,0.05, t-test), to range between 76.92% (GSE20271) and
83.68% (GSE3494). The sensitivity (62.5%) obtained with HG-
133 Plus 2.0 GeneChip (GSE9195; third validation set) lies within
the 95% confidence interval for sensitivity obtained for HG-
U133A GeneChip (CI95%: 61.44 – 87.19%). However, the
specificity (60.0%) obtained with HG-133 Plus 2.0 GeneChip was
lower than the lower limit of the 95% confidence interval for
specificity established with the HG-U133A GeneChip (95%CI:
72.08–88.98%). This indicates, that whereas the candidate PR
Gene Symbol Correlation Coefficient Gene Title
KIF2C 20.41 kinesin family member 2C
20.41
KPNA2 20.41 karyopherin alpha 2 (RAG cohort 1, importin alpha 1)
LAD1 20.41 ladinin 1
LPIN1 20.40 lipin 1
MCAM 20.39 melanoma cell adhesion molecule
MELK 20.40 maternal embryonic leucine zipper kinase
MKI67 20.39 antigen identified by monoclonal antibody Ki-67
OR7E37P 20.39 olfactory receptor, family 7, subfamily E, member 37 pseudogene
PSME4 20.42 proteasome (prosome, macropain) activator subunit 4
PTTG1 20.40 pituitary tumor-transforming 1
SLC7A5 20.40 solute carrier family 7 (cationic amino acid transporter, y+system), member 5
TTK 20.40 TTK protein kinase
Each row in the correlation coefficient column represents a probe set. Genes, whose levels of expression are reported to correlate with PR are marked in bold. Genes
that occur in the signature predictive of ER status are marked in italics. Those genes whose levels of expression have been reported in literature to correlate with ER
status are marked by an asterisk. The list of genes is divided into those with positive and negative correlation (-) coefficients. For detailed information on the probe sets
see Table S3.
doi:10.1371/journal.pone.0026023.t005
Table 5. Cont.
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determining PR status on HG-U133A and HG-U133 Plus 2.0
GeneChips, it provides a lower specificity for determining PR
status on HG-U133 Plus 2.0 arrays compared to the HG-U133A
arrays for which it was developed.
Discussion
Global gene expressionprofiling is widely used in cancer research
and the results of these analyses are generally accessible to the
scientific community in public repositories. However, these profiles
rarely have accessory information concerning the clinically
established status of PR, ER or that of ERBB2. Knowledge of the
expression of the aforementioned markers could be used to mine
publically available gene expression profiles for candidate molecular
targets thus aiding efforts to expand the armamentarium of
anticancer therapies targeted to these breast tumor subtypes.
Previous studies have demonstrated a correlation between
mRNA levels and clinical receptor status as established by IHC,
FISH and ligand-binding assays using breast tumor samples
[57,58,59]. Means have also been established for statistical
thresholds for ESR1, PR and ERBB2 transcript levels to assign
their expression status in profiled breast tumor samples [14,31,32].
These methods use a single probe set to predict ER, PR or ERBB2
status of breast tumor samples. Whereas the latter assays provide
good sensitivity for determining ER status and good specificity for
those of PR and ERBB2, improvements of these parameters would
be desirable to more accurately predict the status of the expression
of these genes in breast tumor gene expression profiles.
Our study sought to establish a more accurate specificity for
predicting ER status and increased sensitivity for predicting those
of PR and ERBB2 while maintaining or improving the sensitivity
to predict ER status and to similarly maintain or improve the
specificity to predict PR and ERBB2 status. Predictive signatures
were developed based on data collected from HG-U133A
GeneChips. However, additional GeneChip arrays, HG-U133
Plus 2.0, have been developed (http://media.affymetrix.com/
support/technical/datasheets/hgu133arrays_datasheet.pdf), and
Table 6. Correlation of microarray–based expression profiling data with routinely established PR status.
Total
PR status defined
by predictor Clinical PR status
Negative Positive p-value*
Training GSE3494 251 Negative 45 31 2.3?10
216
Positive 16 159
GSE3494** 251 Negative 29 17 ,3.3?10
210
Positive 32 173
Validation GSE20271 144 Negative 63 15 6.1?10
212
Positive 16 50
GSE20194 278 Negative 107 22 ,2.2?10
216
Positive 50 99
GSE9195 79 Negative 9 24 0.1484
Positive 6 40
*Fisher’s exact test.
**The analysis was performed by using the ‘‘best probe set’’ (‘‘219197_s_at’’). The rest of analyses were performed by using the 51-gene PR signature.
doi:10.1371/journal.pone.0026023.t006
Figure 6. PR status determination: sensitivity (‘+’) and specificity (‘-’) obtained with two different microarray-based methods. The
improved feature is highlighted by gray background. Datasets GSE3494, GSE20271 and GSE20194 were profiled on HG-U133A GeneChips; GSE9195
was profiled on HG-U133 Plus 2.0GeneChips. * Training set.
doi:10.1371/journal.pone.0026023.g006
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Therefore, another goal of our study was to examine the predictive
capacity of our signatures using transcript profiles performed on
both HG-U133A and HG-133 Plus 2.0 GeneChips to learn
whether our predictive signatures perform independently of the
nature of the GeneChips used to identify them.
Gene signature predictive of ER status
The gene signature reported here comprises 24 annotated
genes. One of these genes is ESR1 (estrogen receptor alpha)
whereas 11 others have been reported to correlate with the
expression of ESR1 or to be directly regulated by ER
[36,37,38,39,40,41,42,43,44]. Several of the identified genes are
represented by a number of probe sets in the gene signature
indicating that these genes have a stable correlation with ER
status. Interestingly, one additional gene was found to be reported
to positively correlate with PR status [45]. This finding is
supported by reports that ER and PR status often correspond
with each other [60]. However, this gene was not identified in our
PR-predictive gene signature. A plausible explanation for the latter
is that we used a high correlation coefficient cutoff to identify the
genes belonging to the ER-predictive signature, and hence this
gene might have been eliminated during the gene selection
process.
Because previously reported methods used a single probe set to
determine the hormone and ERBB2 status of tumors, we wished to
learn whether a single probe set from the 24-gene ER signature
performed as well as the whole signature. To this end we selected
the probe set with the highest Spearman rank correlation to the
ER status of the sample as the ‘‘best probe set’’. The best probe set
thus identified is identical to that identified in previous studies to
determine ER status [14,31]. The levels of sensitivity and
specificity of ER status prediction by using the ‘‘best probe set’’
were lower than the sensitivity of the prediction by using the 24-
gene ER signature, indicating that the signature outperformed the
‘‘best probe set’’.
Previous methods [14,31] yielded high sensitivity, but a
relatively low specificity for predicting ER status (Figure 2).
Therefore, we wondered whether we could improve the specificity
of ER status prediction by identifying a gene signature to predict
ER status. Indeed, our ER-predictive gene signature provides a
significantly higher specificity, while maintaining the level of
sensitivity. The ER-predictive gene signature we identified was
derived by analyzing gene expression data from breast tumor
RNA samples profiled on the HG-U133A GeneChip arrays.
However, we were unable to find an HG-U133 Plus 2.0 dataset
with accompanying clinical information concerning ER status.
Future studies will examine the predictive potential of the ER gene
signature on HG-U133 Plus 2.0 arrays.
Gene signature predictive of PR status
The signature predictive of PR status consists of 51 annotated
genes, which include the PGR (progesterone receptor), and 9 genes
(AURKA, BUB1, GATA3, GLI3, STC2, CDC20, CENPA, HJURP
and MKI67) that have previously been demonstrated to correlate
with PGR expression (Table 5; [47,48,49,50,51,52,61]). Interest-
ingly, 11 genes (STC2, GATA3, CA12, FAM176B, GAMT, GFRA1,
IL6ST, KDM4B, SCUBE2, LIV1, and an ‘unknown’ gene; Tables 1
and 5) out of the 51 genes constituting the PR-predictive signature
also appear in our 24-gene ER-predictive signature. These
findings are in agreement with other studies reporting that ER
and PR status often correlate with each other [60]. Notably, the
probe set for the only gene lacking annotation appears in both
signatures predictive of PR and ER status indicating a strong
connection of the gene reflected by this probe set to ER and PR
status. The PR-status predictive signature comprised 2 other genes
(HPN and MAPT) whose expression is positively correlated with
ER expression [37,56]. However, these genes were not identified
in our ER-predictive gene signature, probably due to the fact that
they had a lower correlation coefficient with ER status than the
cutoff established to identify the ER-predictive signature.
The ‘‘best probe set’’ selected from the PR predictive signature
was ‘‘219197_s_at’’ (SCUBE2). Expression of this gene has not
been reported to correlate with PR status of human, however, this
gene appears also in our 24-gene ER-predictive signature, and, as
has been mentioned earlier, there are studies showing that ER and
PR status often show correlation with each other. Specificity of
prediction using the ‘‘best probe set’’ was very low, reaching only
47.54% and prediction accuracy and PPV of the were lower than
the ones obtained with the 51-gene PR-predictive signature.
Therefore, we concluded, that the PR-predictive signature
outperformed the single ‘‘best probe set’’.
Previous method [32] yielded high specificity, but a relatively
low sensitivity for predicting PR status (Figure 6). Therefore, we
wondered whether we could improve the sensitivity of PR status
prediction by identifying a gene signature to predict PR status. By
using our gene signature predictive of PR status, we significantly
improved the level of sensitivity, while not reducing the level of
specificity, as compared to the same measures obtained with 1
probe set (Figure 6).
When tested on data obtained from HG-U133 Plus 2.0
GeneChip arrays, the results differed from the ones obtained
from datasets profiled on HG-U133A arrays (Figure 6 and
Table 6), indicating, that our candidate PR gene signature needs
to be modified to predict PR status of tumor samples profiled on
other array types. A plausible explanation for the lower level of
performance of the predictive signature on data obtained from
HG-U133 Plus 2.0 arrays could be the technical differences in the
design of the arrays belonging to HG-U133A and HG-U133 Plus
2.0 types: HG-U133 Plus 2.0 arrays belong to a newer generation
of GeneChip arrays, which contain improvements, that result in
higher resolution, sharpness, definition and signal uniformity (http:
//media.affymetrix.com/support/technical/technotes/expression_
comparison_technote.pdf). Such technical differences could affect
information obtained for the probe sets that were included in our PR
signature, among other probe sets.
Gene signature predictive of ERBB2 status
The ERBB2 predictive gene signature consists of 14 annotated
genes, including ERBB2 and 5 genes (CRK7, GRB7, PERLD1,
PPARBP, and STARD3) located within the ERBB2 17q12-q21
amplicon [46]. Several of these genes are represented by multiple
probe sets in the ERBB2-predictive gene signature indicating their
stable correlation with ERBB2 status.
The ‘‘best probe set’’ selected from the ERBB2 predictive
signature was ‘‘203497_at’’, representing PPARBP, a gene, located
within the ERBB2 17q12-q21 amplicon [46]. The performance of
this ‘‘best probe set’’ was tested on two training sets (GSE2603 and
GSE20271), that were used to derive the 14-gene ERBB2
signature. The first training set (GSE2603) could not provide us
with a clear cutoff for the Spearman rank correlation used to
determine the optimal number of genes for the signature (Figure 3).
Therefore we needed to test the second training set (GSE20271) as
well. The sensitivity of prediction by using the ‘‘best probe set’’ for
the second training set (GSE20271) was very low, reaching
40.91%. Therefore, we concluded, that the ERBB2-predictive
signature outperformed the single ‘‘best probe set’’.
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levels for predicting ERBB2 status from gene expression profiles
using a single probe set (216836_s_at); however, the sensitivity of
this method was relatively low. By contrast the specificity levels of
our 14-gene signature was unchanged from that reported
previously but the sensitivity levels were improved. Additionally,
the ERBB2-predictive gene signature also successfully predicted
ERBB2 status of gene expression profiles obtained by employing
the HG-U133 Plus 2.0 GeneChip (Figure 4 and Table 4).
In summary our findings demonstrate that small gene signatures
can be identified in patient breast tumor gene expression profiles
that accurately predict ER, PR and ERBB2 status.
Methods
Gene expression profiles
As shown in Table 7, to define ER status we used raw CEL files
from the following datasets: GSE3494 (247 samples), GSE2034
(286 samples), GSE7390 (198 samples), GSE2603 (97 samples),
GSE20271 (144 samples), and GSE20194 (278 samples); to define
ERBB2 status we used raw CEL files from GSE2603 (88 samples),
GSE20271 (144 samples), GSE20194 (278 samples), and
GSE16446 (93 samples); finally to define PR status we used
GSE3494 (251 samples), GSE20271 (144 samples), GSE20194
(278 samples), and GSE9195 (79 samples). These aforementioned
datasets were downloaded from the Gene Expression Omnibus
depository [33]. All samples were profiled on Affymetrix HG-
U133A GeneChips (Affymetrix, Santa Clara, CA, USA), with the
exception of GSE16446 and of GSE9195, which employed
Affymetrix HG-U133 Plus 2.0 GeneChips. All the samples were
pre-processed with fRMA [62].
Clinical definition of hormonal receptors status and
ERBB2 status
Table 7 shows the sources of the samples and the methods used
to obtain the clinical status of the ER and PR and that of ERBB2.
Filtering repeated samples across datasets
Samples for 2 datasets (GSE20271 and GSE20194) were
contributed by the University of Texas M. D. Anderson Cancer
Center (MDACC, Houston, TX, USA), and as a result, there were
34 samples that were present in both datasets. For all analyses
performed in the present study, these repeated samples were
removed from GSE20271, reducing the number of usable samples
from 178 to 144.
Single-probe set estimations
Comparing predictive capacity of our signatures to predictive
capacity of single probe sets reported to be used in the literature.
For all datasets obtained from HG-U133A GeneChips, the one
probe set estimation was performed by using ‘‘205225_at’’ for
determining ER status [14,31] , ‘‘216836_s_at’’ for determining
ERBB2 status [14,31], and ‘‘208305_at’’ for determining PR
status [32]. Hormone and ERBB2 status was determined by fitting
Gaussian distributions into the distribution of expression values of
the examined probe set using Expectation-Maximalization (EM)
algorithm [63], similar to the method described by Rody et al [31]
and by Lehmann et al [32]. For GSE16446 dataset, which was
obtained from HG-U133 Plus 2.0 GeneChips, we used the data on
bimodal ERBB2 status supplied with the samples.
Comparing predictive capacity of our signatures to predictive
capacity of single probe sets with the highest Spearman rank
correlation to the hormone and ERBB2 status (‘‘best probe set’’).
These comparisons were performed for the training sets used to
establish the predictive signatures. The probe set with the highest
Spearman rank correlation with ER status was ‘‘205225_at’’
(Spearman rank correlation=0.50), the same probe set as the one
used in literature [14,31]. We used ‘‘203497_at’’ (Spearman
rank correlation=0.45) for determining ERBB2 status and
‘‘219197_s_at’’ (Spearman rank correlation=0.44) for determin-
ing PR status. Hormone and ERBB2 status was determined in the
same way as in the previous single-probe set estimation, by fitting
Gaussian distributions using Expectation-Maximalization algo-
rithm.
Finding gene signatures predictive of ER, PR or ERBB2
clinical status of the tumor samples
Figure 7 describes the algorithm used to find gene signatures
predictive of ER, PR or ERBB2 clinical status of the samples. First,
global gene expression profiles for the whole training dataset were
examined and for each probe set Spearman rank correlation
coefficient between its expression levels and clinical status of
interest was calculated. The probe sets were sorted by the
correlation coefficient, and several groups of genes were selected
Table 7. Sources of the samples and methods used to obtain the clinical information about the samples.
Total number of
profiled samples ER assessment PR assessment ERBB2 assessment
IHC EIA* Other assay IHC Biochemical assay IHC or FISH
GSE2034 286 9 277 - - - -
GSE3494 251 - - 247 bioche-mical
assay
251 -
GSE7390 198 198 - - - - -
GSE2603 121 97 either IHC, EIA or
Biochemical assay
- - 88 IHC
GSE20271 144 144 - - 144 - 144 either IHC or FISH
GSE20194 278 278 - - 278 - 278 either IHC or FISH
GSE16446 120 - - - - - 93 FISH
GSE9195 79 - - 79 Ligand binding
*enzymatic immunoassay – EIA [64].
doi:10.1371/journal.pone.0026023.t007
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selected by using a lower cutoff would contain all the genes
belonging to a group selected by using a higher cutoff and
additional genes that were filtered out by the higher cutoff. Each
group of genes was used for k-means clustering of the samples, in
order to define samples with positive and negative status. Then
specificity and sensitivity were calculated. Group of genes that led
to the highest combination of specificity and sensitivity was defined
as a gene signature with optimal predictive ability for the clinical
status of interest for the samples in the training set. The same
group of genes was used on validation sets, and specificity,
sensitivity, accuracy, PPV and NPV were calculated. To derive
gene signature predictive of ERBB2 status 2 training sets were
needed, since the first set provided constant specificity and
sensitivity values for multiple correlation cutoffs.
Supporting Information
Table S1 Gene signature predictive of ER status. Because
the gene signature contains only genes with positive Spearman
correlation coefficients there is no division based on the
coefficients. Genes were sorted alphabetically by their symbol.
(XLS)
Table S2 Gene signature predictive of ERBB2 status.
The list of genes is divided into those with positive and negative
correlation coefficients. Genes were sorted alphabetically by their
symbol.
(XLS)
Table S3 Gene signature predictive of PR status. The list
of genes is divided into genes with positive and negative correlation
coefficients. Genes were sorted alphabetically by their symbol.
(XLS)
Table S4 Hormone and ERBB2 receptors status deter-
mination: sensitivity (‘+’) and specificity (‘-’) obtained
with two different microarray-based methods. ‘‘One
probe set’’-by using the single probe set described in the literature.
‘‘Signature’’-by using our predictive signature.
(XLS)
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